The Hidden Burden of Fractures in People Living With HIV

Overview

Journal JBMR Plus

Publisher Oxford University Press

Date 2018 Oct 5

PMID 30283906

Citations 20

Authors

Melissa O Premaor

Juliet E Compston

Affiliations

Soon will be listed here.

Abstract

The survival of people living with human immunodeficiency virus (HIV) has increased markedly since the advent of antiretroviral therapy (ART). However, other morbidities have emerged, including osteoporosis. The estimated incidence of fractures at any site in people living with HIV ranges from 0.1 per 1000 person-years to 8.4 per 1000 person-years: at least twice that of people without HIV. This increased risk seems to be related to HIV itself and its treatment. Risk factors for bone disease in HIV-positive (HIV) subjects include both classical risk factors for osteoporosis and fracture and factors linked to HIV itself, such as inflammation, reconstitution syndrome, low CD4, ART, and co-infection with hepatitis B and C viruses. The risk of fractures in these individuals can be at least partially assessed by measurement of BMD and the Fracture Risk Assessment Tool (FRAX™). Only alendronate and zoledronic acid have been studied in HIV individuals; both show beneficial effects on BMD, although data on fracture reduction are not available. © 2018 The Authors. Published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.

Citing Articles

Prevalence of HIV-associated osteoporosis and fracture risk in midlife women: a cross-sectional study in Zimbabwe.

Madanhire T, Breasail M, Kahari C, Kowo-Nyakoko F, Ebeling P, Ferrand R J Bone Miner Res. 2024; 39(10):1464-1473.

PMID: 39180721 PMC: 11425699. DOI: 10.1093/jbmr/zjae138.

Unilateral avascular necrosis of the right hip in an HIV patient with tearing of the rectus femoris and adductor longus muscles.

Raza S, Khan N BMJ Case Rep. 2024; 17(5).

PMID: 38802252 PMC: 11130611. DOI: 10.1136/bcr-2023-258709.

Sarcopenic obesity and reduced BMD in young men living with HIV: body composition and sex steroids interplay.

De Vincentis S, Greco C, Fanelli F, Decaroli M, Diazzi C, Mezzullo M J Endocrinol Invest. 2024; 47(11):2715-2730.

PMID: 38643322 PMC: 11473605. DOI: 10.1007/s40618-024-02375-6.

Bone mass, fracture risk, and associated factors in postmenopausal women living with HIV.

Leite-Silva P, Pinheiro R, Barbosa-Ferreira J, Balieiro A, Sabido M, Lacerda M Menopause. 2023; 31(1):46-51.

PMID: 38113435 PMC: 11812646. DOI: 10.1097/GME.0000000000002293.

Prevalence of and risk factors for vertebral fracture and low bone mineral density among Peruvian women aging with HIV.

Cabrera D, Cornejo M, Slotkin R, Pinedo Y, Yu W, Guan W Arch Osteoporos. 2023; 18(1):64.

PMID: 37160770 PMC: 10170032. DOI: 10.1007/s11657-023-01250-w.

References

Papapoulos S, Lippuner K, Roux C, Lin C, Kendler D, Lewiecki E . The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015; 26(12):2773-83. PMC: 4656716. DOI: 10.1007/s00198-015-3234-7. View

Beaupere C, Garcia M, Larghero J, Feve B, Capeau J, Lagathu C . The HIV proteins Tat and Nef promote human bone marrow mesenchymal stem cell senescence and alter osteoblastic differentiation. Aging Cell. 2015; 14(4):534-46. PMC: 4531068. DOI: 10.1111/acel.12308. View

Martin A, Bloch M, Amin J, Baker D, Cooper D, Emery S . Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009; 49(10):1591-601. DOI: 10.1086/644769. View

Santos W, Santos W, Paes P, Ferreira-Silva I, Santos A, Vercese N . Impact of Strength Training on Bone Mineral Density in Patients Infected With HIV Exhibiting Lipodystrophy. J Strength Cond Res. 2015; 29(12):3466-71. DOI: 10.1519/JSC.0000000000001001. View

Cozzolino M, Vidal M, Arcidiacono M, Tebas P, Yarasheski K, Dusso A . HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003; 17(4):513-20. DOI: 10.1097/00002030-200303070-00006. View

Rietschel P, Corcoran C, Stanley T, Basgoz N, Klibanski A, Grinspoon S . Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis. 2000; 31(5):1240-4. DOI: 10.1086/317457. View

Stephens K, Rubinsztain L, Payan J, Rentsch C, Rimland D, Tangpricha V . DUAL-ENERGY X-RAY ABSORPTIOMETRY AND CALCULATED FRAX RISK SCORES MAY UNDERESTIMATE OSTEOPOROTIC FRACTURE RISK IN VITAMIN D-DEFICIENT VETERANS WITH HIV INFECTION. Endocr Pract. 2015; 22(4):440-6. PMC: 5369646. DOI: 10.4158/EP15958.OR. View

Yin M, McMahon D, Ferris D, Zhang C, Shu A, Staron R . Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2009; 95(2):620-9. PMC: 2840861. DOI: 10.1210/jc.2009-0708. View

Kurita T, Kitaichi T, Nagao T, Miura T, Kitazono Y . Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan. Pharmacoepidemiol Drug Saf. 2014; 23(4):372-81. PMC: 4230469. DOI: 10.1002/pds.3588. View

10.

Brown T, Moser C, Currier J, Ribaudo H, Rothenberg J, Kelesidis T . Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. J Infect Dis. 2015; 212(8):1241-9. PMC: 4577040. DOI: 10.1093/infdis/jiv194. View

11.

Bernardino J, Mocroft A, Mallon P, Wallet C, Gerstoft J, Russell C . Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV. 2015; 2(11):e464-73. DOI: 10.1016/S2352-3018(15)00181-2. View

12.

Arnsten J, Freeman R, Howard A, Floris-Moore M, Lo Y, Klein R . Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007; 21(5):617-23. PMC: 2426821. DOI: 10.1097/QAD.0b013e3280148c05. View

13.

Yin M, Shu A, Zhang C, Boutroy S, McMahon D, Ferris D . Trabecular and cortical microarchitecture in postmenopausal HIV-infected women. Calcif Tissue Int. 2013; 92(6):557-65. PMC: 3656136. DOI: 10.1007/s00223-013-9716-8. View

14.

Hileman C, Eckard A, McComsey G . Bone loss in HIV: a contemporary review. Curr Opin Endocrinol Diabetes Obes. 2015; 22(6):446-51. PMC: 4663974. DOI: 10.1097/MED.0000000000000200. View

15.

Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M . Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011; 53(11):1130-9. DOI: 10.1093/cid/cir626. View

16.

Rozenberg S, Lanoy E, Bentata M, Viard J, Valantin M, Missy P . Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120). AIDS Res Hum Retroviruses. 2012; 28(9):972-80. DOI: 10.1089/AID.2011.0224. View

17.

Yong M, Elliott J, Woolley I, Hoy J . Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr. 2011; 57(3):205-10. DOI: 10.1097/QAI.0b013e31821ecf4c. View

18.

Woodward C, Hall A, WILLIAMS I, Madge S, Copas A, Nair D . Tenofovir-associated renal and bone toxicity. HIV Med. 2009; 10(8):482-7. DOI: 10.1111/j.1468-1293.2009.00716.x. View

19.

Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, Diazzi C . Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS One. 2011; 6(12):e28512. PMC: 3235128. DOI: 10.1371/journal.pone.0028512. View

20.

Compston J . HIV infection and bone disease. J Intern Med. 2016; 280(4):350-8. DOI: 10.1111/joim.12520. View